In:
Open Forum Infectious Diseases, Oxford University Press (OUP), Vol. 2, No. 4 ( 2015-12-01)
Abstract:
Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect was neuropathy. We propose that LNZ should be reclassified among bactericidal second-line drugs.
Type of Medium:
Online Resource
ISSN:
2328-8957
Language:
English
Publisher:
Oxford University Press (OUP)
Publication Date:
2015
detail.hit.zdb_id:
2757767-3
Bookmarklink